Cd40 ligand adjuvant for respiratory syncytial virus

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/155 (2006.01) A61K 38/17 (2006.01) A61K 39/39 (2006.01)

Patent

CA 2399790

The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.

La présente invention concerne des méthodes et des adjuvants destinés à intensifier une réponse immunitaire dirigée contre le virus RSV chez un hôte, ces méthodes et ces adjuvants comprenant une source d'une protéine de liaison CD40. Cette protéine de liaison CD40 est de préférence CD40L, la source étant un vecteur comprenant un promoteur fonctionnellement relié à une région de codage CD40L. La réponse immunitaire intensifiée produite par les adjuvants et les méthodes de la présente invention implique une augmentation de l'expression des cytokines Th1 et de la production d'anticorps.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Cd40 ligand adjuvant for respiratory syncytial virus does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cd40 ligand adjuvant for respiratory syncytial virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cd40 ligand adjuvant for respiratory syncytial virus will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1380070

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.